A Phase 1, Multicenter, Single-Dose, Dose-Escalation, Safety and Tolerability Study of MDX-1342 (Anti-CD19 Human Monoclonal Antibody) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis.

Trial Profile

A Phase 1, Multicenter, Single-Dose, Dose-Escalation, Safety and Tolerability Study of MDX-1342 (Anti-CD19 Human Monoclonal Antibody) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 May 2013

At a glance

  • Drugs MDX 1342 (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Dec 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 27 Jan 2009 Official title updated from ClinicalTrials.gov.
    • 03 Dec 2008 Planned number of patients changed from 90 to 50, based on information from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top